Prucalopride

Clinical Pharmacist

Volumn 3, Issue 2, 2011, Pages 55-57

  Herring, Christopher ^a  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450; ERYTHROMYCIN; HALOPERIDOL; KETOCONAZOLE; PRUCALOPRIDE; QUINIDINE; VERAPAMIL;

ABDOMINAL PAIN; ADJUVANT THERAPY; ANOREXIA; ARTICLE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DEFECATION HABIT; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEVER; FLATULENCE; HEADACHE; HEART PALPITATION; HUMAN; INTESTINE SOUND; MALAISE; NAUSEA; OUTCOME ASSESSMENT; PHARMACY; POLLAKISURIA; QT PROLONGATION; RECTUM HEMORRHAGE; SIDE EFFECT; TREATMENT RESPONSE; TREMOR; VOMITING;

EID: 84857249153     PISSN: 17589061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. London New Drugs Group. Prucalopride for chronic constipation in women. August 2010. www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific-Reviews (accessed 9 November 2010).
2. Joint Formulary Committee. British National Formulary 60th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2010.
3. National Institute for Health and Clinical Excellence. Prucalopride for the treatment of chronic constipation in women. December 2010. www.nice.org.uk/ta211 (accessed 17 December 2010).
4. Movetis Ltd. Summary of product characteristics: Resolor. October 2010. www.medicines.org.uk (accessed 9 November 2010).
5. Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo controlled study. Neurogastroenterology and Motility 2009:21:1256-63.
6. Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58:357-65.
7. Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical Trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12 week, randomised, double-blind, placebo-controlled study. Alimentary Pharmacology and Therapeutics 2008;29:315-28.
8. Müller-Lissner S, Rykx A, Kerstens R, et al. A double blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterology and Motility 2010;22:991-8.
9. Arizona Centre for Education and Research on Therapeutics. www.azcert.org/index.cfm (accessed 12 November 2010).